Načítá se...
CDK4/6 inhibition in luminal breast cancer
Endocrine therapy represents the basis for the treatment of estrogen receptor-positive breast cancer, but several tumors harbor intrinsic resistance and acquired resistance to endocrine therapy is inevitable in metastatic disease. Combination strategies of endocrine therapy with targeted agents are...
Uloženo v:
| Vydáno v: | Memo |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer Vienna
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4923084/ https://ncbi.nlm.nih.gov/pubmed/27429659 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12254-016-0268-2 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|